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Abstract
Hydrogen sulfide (H2S), a novel gaseous messenger, is synthesized endogenously from L-cysteine by two pyridoxal-59-
phosphate-dependent enzymes, cystathionine b-synthase (CBS) and cystathionine c-lyase (CSE). S-propargyl-cysteine (SPRC)
is a slow H2S releasing drug that provides cysteine, a substrate of CSE. The present study was aimed to investigate the
effects of SPRC in an in vivo model of acute pancreatitis (AP) in mice. AP was induced in mice by hourly caerulein injections
(50 mg/kg) for 10 hours. Mice were treated with SPRC (10 mg/kg) or vehicle (distilled water). SPRC was administered either
12 h before or 3 h before the induction of pancreatitis. Mice were sacrificed 1 h after the last caerulein injection. Blood,
pancreas and lung tissues were collected and processed to measure the plasma amylase, plasma H2S, myeloperoxidase
(MPO) activities and cytokine levels in pancreas and lung. The results revealed that significant reduction of inflammation,
both in pancreas and lung was associated with SPRC given 3 h prior to the induction of AP. Furthermore, the beneficial
effects of SPRC were associated with reduction of pancreatic and pulmonary pro-inflammatory cytokines and increase of
anti-inflammatory cytokine. SPRC administered 12 h before AP induction did not cause significant improvement in
pancreatic and lung inflammation. Plasma H2S concentration showed significant difference in H2S levels between control,
vehicle and SPRC (administered 3 h before AP) treatment groups. In conclusion, these data provide evidence for protective
effects of SPRC in AP possibly by virtue of its slow release of endogenous H2S.
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Introduction
Hydrogen sulfide (H2S), a novel endogenous gaseous mediator,
has been explored recently for its physiological and pathological
roles. H2S is synthesized from L-cysteine, a sulfur-containing
amino acid substrate [1], facilitated by the two key enzymes
Cystathionine c-lyase (CSE, EC4.4.1.1) and cystathionine b-
synthase (CBS, EC4.2.1.22). Numerous animal studies have shown
the beneficial effects of H2S, especially in cardiovascular and
neurological disorders [2]. But the role of H2S in inflammation is
only recently beginning to emerge and the exact role of H2Si n
inflammation is still not clearly understood. While pro-inflamma-
tory effects of H2S were observed in various models of
inflammation, some studies have also reported anti-inflammatory
effects of H2S [3–5]. In the former studies, plasma H2S level, tissue
H2S synthesizing enzyme activity and CSE expression were
increased in inflammation and inhibition of H2S synthesis by a
CSE inhibitor reduced the inflammation [6–11]. However,
treatments with either H2S-releasing non steroidal anti-inflamma-
tory drugs (e.g. s-diclofenac, ATB-429) or H2S donors (e.g. sodium
hydrosulfide (NaHS), Lawesson’s reagent, N-acetylcysteine,
GYY4137) have also reported anti-inflammatory activity in
inflammation [12–18]. Thus in addition to blocking endogenous
H2S in inflammation, several studies are also in progress to
develop sustained-releasing H2S donors to combat inflammation
more effectively.
Acute pancreatitis (AP) is an acute inflammatory disorder of
pancreas. It is potentially lethal and the incidence of AP has been
increasing over recent years. Approximately 20–25% of the
patients suffers a severe attack, and 30–50% of these will die
[19,20]. Although the mortality rate following pancreatitis has
significantly improved over the past few decades, treatment
options currently available are limited, and predominantly aimed
at supportive therapy. Several pharmacological agents have been
studied in animal models of AP and in clinical settings of
pancreatitis, with variable success [19,21].
Our group has previously shown the anti-inflammatory effects
of low doses of NaHS in mouse model of AP [22]. However due to
the narrow therapeutic window and potentially toxic effects
associated with high doses of NaHS, researchers are focusing on
developing novel H2S donors [22]. H2S-releasing non-steroidal
anti-inflammatory drugs (NSAID) like ACS15 and ATB-429 and
other drugs like GYY4137 have demonstrated anti-inflammatory
effects in vivo/vitro studies [12–16]. S-propargyl-cysteine (SPRC) is
a structural analog of S-allyl cysteine (SAC) with a common
cysteine-containing structure [23]. SAC, a water-soluble organo-
sulfur compound of aged garlic extract (AGE), is well known for its
cardio-protective and anti-cancer effects [24]. Research studies
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32574have shown protective effects of SAC against carbon tetrachloride-
induced oxidative stress and pulmonary fibrosis and carbon
tetrachloride-induced acute liver injury in rats [25,26]. SAC has
been shown to be a substrate of CSE and also induce CSE
expression resulting in an increase in H2S production [27].
Interestingly, SPRC has been reported to show protective effects
against myocardial infarctions in both adult rat hearts and
neonatal cardiomyocytes through H2S pathway [23]. These novel
cysteine containing compounds (SPRC, SAC and S-propyl-L-
cysteine (SPC)) have shown to reduce the deleterious effects of
oxidative stress in rat acute myocardial infarction [28].
In this study, we aimed to investigate the effects of SPRC in
caerulein-induced AP in mice to test the hypothesis that SPRC
could be beneficial against AP. In addition to the evaluation of
inflammation in the pancreas and lung, we also determined the
plasma H2S levels with SPRC treatment.
Materials and Methods
Experimental procedures
All animal experiments were approved by the Animal Ethics
Committees of National University of Singapore, Singapore
(permit number 807/05) and University of Otago (permit number
CET1/10) and were carried out in accordance with established
International Guiding Principles for Animal Research. Swiss mice
(male, 20–25 g) were used and maintained in the Animal Housing
Unit in an environment with controlled temperature (21–24uC)
and lighting (12 h light-dark cycle). Standard laboratory chow and
drinking water were provided ad libitum. A period of at least 2 days
was allowed for the animals to acclimatize before any experimen-
tal procedures were undertaken.
Induction of AP
Caerulein was obtained from Bachem (Bubendorf, Switzerland).
SPRC was synthesized by Dr Zhu Yi Zhun. Mice were randomly
assigned to four groups (n=10 per group). Group 1: Animals were
given hourly intraperitoneal (i.p.) injections of normal saline
(CTRL group). Group 2: Animals were treated with distilled water
(DW) followed by hourly i.p. injections of caerulein (50 mg/kg)
over 10 h to induce AP (Veh+Cae). Group 3: Animals were
treated with SPRC (10 mg/kg), 3 h before hourly injections of
caerulein (50 mg/kg) over 10 h (SPRC 3 h+Cae). Group 4:
Animals were treated with SPRC (10 mg/kg), 12 h before hourly
injections of caerulein (50 mg/kg) over 10 h (SPRC 12 h+Cae).
SPRC was dissolved in DW. One hour after the last caerulein
injection animals were sacrificed by an i.p. injection of a lethal
dose of pentobarbital (50 mg/kg: Nembutal, CEVA Sante
Animale, Naaldwijk, Netherlands). Blood, pancreas and lung
tissues were collected. Samples of pancreas and lung were
weighed, snap frozen in liquid nitrogen and then stored at
280uC for subsequent measurement of tissue myeloperoxidase
(MPO) activities, and cytokines as described in detail below.
Harvested heparinized blood was centrifuged (10,000 rpm,
10 min, 4uC) and the plasma was aspirated and stored at
280uC for subsequent detection of plasma amylase and H2S.
Parts of the pancreas and lung were also fixed in 10% v/v neutral
phosphate-buffered formalin for more than 48 h and then were
processed for histology.
Amylase estimation
Plasma amylase activity was measured using a kinetic
spectrophotometric assay. Plasma samples were incubated with
the Amylase reagent (Sigma, St. Louis, Mo) for 2 min at 37uC,
and absorbance was measured every min for the subsequent
2 min at 405 nm using manufacturer’s instructions [7,13]. The
resulting change in absorbance was used to calculate the amylase
activity.
MPO estimation
Sequestration of inflammatory cells in pancreas and lung were
quantified by measuring tissue MPO activity [7,13]. Tissue
samples were thawed, homogenized in 20 mM phosphate buffer
(pH 7.4), centrifuged (13,000 rpm, 10 min, 4uC), and the resulting
pellet resuspended in 50 mM phosphate buffer (pH 6.0) contain-
ing 0.5% w/v hexadecyltrimethylammonium bromide (Sigma).
The suspension was subjected to four cycles of freezing and
thawing and further disrupted by sonication (40 s). The sample
was then centrifuged (13,000 rpm, 5 min, 4uC), and the
supernatant was used for the MPO assay. The sample was mixed
with equal volume of 1-component tetramethylbenzidine (TMB)
substrate (Sureblue), incubated for a fixed time, and then
terminated by adding equal volume of 2N H2SO4. The
absorbance was measured at 450 nm and corrected for the
calculated DNA of the tissue sample [29]. Results were expressed
as enzyme activity (fold increase over corresponding saline injected
control groups).
Morphological examination
Paraffin-embedded pancreas and lung samples were sectioned
(5 mm), stained with hematoxylin/eosin (H and E) and were
examined with light microscopy by an experienced observer
blinded with respect to different experimental groups. Acinar-cell
injury/necrosis was quantitated by morphometry as described [7].
For these studies, 10 randomly chosen microscopic fields were
examined for each tissue sample and the extent of acinar-cell
injury/necrosis was expressed as the percent of the total acinar
tissue that was occupied by areas meeting the criteria for injury/
necrosis. Those criteria were defined as either (i) the presence of
acinar-cell ghosts or (ii) vacuolization and swelling of acinar cells
and the destruction of the histoarchitecture of whole or parts of the
acini, both of which had to be associated with an inflammatory
reaction. Capillary-alveolar membrane thickness was visually
estimated [29] on a scale ranging from 0 to 4, with 0 being the
thinnest and 4 the thickest as observed in the course of these
experiments.
Enzyme-linked immunosorbent assay (ELISA) of cytokines
The levels of cytokines (IL-1b, IL-6, IL-10 and TNF-a) were
measured in pancreas and lung tissue homogenate by a sandwich
ELISA using DuoSet ELISA kits. Briefly, anti-cytokine primary
antibodies were coated onto 96-well ELISA plates and incubated
overnight at room temperature. Samples and standards were
added to the wells and incubated for 2 h, the wells were washed,
and a biotinylated goat anti-mouse cytokines antibodies were
added for 2 h. Plates were washed again, and streptavidin
antibodies conjugated to HRP were added for 20 min. After a
further wash, TMB was added for color development, and the
reaction was terminated with 2 N H2SO4. Absorbance was
measured at 450 nm. Cytokine concentrations of samples were
estimated from the standard curve. The cytokine concentration
was then corrected for the DNA content of the tissue [30].
Measurement of plasma H2S
Aliquots (300 ml) of plasma were mixed with distilled water
(250 ml), zinc acetate (1% w/v, 150 ml), N, N-dimethyl-p-
phenylenediamine sulphate (20 mM; 100 ml) in 7.2 M HCl and
FeCl3 (30 mM; 100 ml) in 1.2 M HCl. After 10 min incubation,
SPRC in Acute Pancreatitis
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mixture to stop the reaction. Samples were centrifuged
(5,000 rpm, 5 min) and then the supernatant (300 ml) was added
into 96- well plates. The absorbance was measured by microplate
reader (SPECTRAFluor Plus, Tecan) at 670 nm. All samples were
assayed in duplicate and H2S was calculated using a calibration
curve of NaHS (3.12–200 mM). The plasma H2S concentrations
were expressed as mM.
Statistical analysis
Data were expressed as the mean 6 standard error of the mean
(s.e.m.). In all figures, vertical error bars denote the s.e.m. The
significance of differences between groups was evaluated by using
analysis of variance (ANOVA) when comparing 3 or more groups.
Tukey and/or LSD method were used as a post hoc test for
comparison among different groups. A P value of ,0.05 was
considered to indicate a significant difference.
Results
Effect of SPRC on plasma amylase in caerulein-induced
AP
The evidence of pancreatic injury induced by caerulein is
generally confirmed by an increase in plasma amylase. Thus the
effect of SPRC treatment on plasma amylase in AP was evaluated,
especially in comparison with the corresponding values in saline
and vehicle pretreated mice. As shown in Fig. 1, mice pretreated
with vehicle or SPRC followed by hourly caerulein injections,
pancreatitis was manifested by significant rise in plasma amylase
activity compared to the mice injected with hourly saline only
(P,0.05). However among the SPRC treatment groups, plasma
amylase was significantly reduced only in mice injected with SPRC
3 h before the induction of pancreatitis compared to vehicle
pretreated mice (P,0.05).
Effect of SPRC on pancreas MPO and histology in
caerulein-induced AP
Pancreatic inflammation was assessed by measuring pancreatic
MPO activity and histology. Measurement of MPO enzyme which
is located in azurophile granules of neutrophils and monocytes
reflects inflammatory cell infiltration in tissue. There was a
significantly elevated MPO in mice administered with vehicle or
SPRC compared to saline (CTRL) group (Fig. 2A). However
within the SPRC treated groups, mice injected with SPRC 3 h
before the induction of pancreatitis showed significant reduction in
MPO activity as compared to vehicle treated mice (Fig. 2A).
Histological examination of sections of pancreas of vehicle
pretreated mice showed evidence of oedema, destruction of
histoarchitecture of the acini and infiltration of inflammatory cells
(Fig. 2B, Veh+Cae). However, among the SPRC groups, mice
given SPRC 3 h before AP induction showed a significantly
reduced pancreatic edema and inflammatory cell infiltration
compared to the vehicle pretreated mice (Fig. 2B, SPRC
3h +Cae). Quantitation of acinar cell injury/necrosis showed that
Veh+Cae treated mice had 4263.6% acinar cell injury/necrosis,
compared with 160.5% for Control, 1060.9% for SPRC
3h +Cae, and 1461.6% for SPRC 12 h+Cae.
Effect of SPRC on AP-associated lung injury
Consistent with our earlier studies, AP induced by 10 hourly
injections of caerulein (50 mg/kg) was associated with lung injury.
As shown in Fig. 3A, caerulein-induced AP was associated with a
significant rise in lung MPO activity compared to saline (CTRL)
group. Histological examination of the lung sections further
confirmed lung injury in AP as evidenced by alveolar thickening
and abundance of inflammatory cell infiltration (Fig. 3B, Veh+-
Cae). However, mice treated with SPRC 3 h before the induction
of pancreatitis had significant reduction in cellular infiltration as
evidenced by decreased lung MPO activity (Fig. 3A, SPRC
Figure 1. Effect of SPRC treatment on plasma amylase activity. Acute pancreatitis was induced by intraperitoneal (i.p.) administration of
caerulein (50 mg/kg, hourly for 10 h). Mice were pre-treated with vehicle or SPRC (10 mg/kg, i.p.), either 3 h or 12 h before the induction of
pancreatitis. One hour after the last caerulein injection, mice were killed by a lethal dose of pentobarbitone (50 mg/kg, i.p.), and plasma amylase
activity was measured as described in ‘‘Materials and methods’’. Key: CTRL, animals injected only with saline (i.p., hourly for 10 h) without the
induction of pancreatitis; Veh+Cae, pre-treatment with vehicle (distilled water) before the induction of pancreatitis; SPRC 3 h+Cae, SPRC injected 3 h
before the induction of pancreatitis; SPRC 12 h+Cae, SPRC injected 12 h before the induction of pancreatitis. Results shown are the mean 6 s.e.m.,
n=10 mice per group.
*P,0.05 when compared to the CTRL group;
#P,0.05 when compared to the Veh+Cae group. CTRL, control; Cae, caerulein;
Veh, vehicle; SPRC, S-propargyl-cysteine.
doi:10.1371/journal.pone.0032574.g001
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protection was not seen in mice administered SPRC 12 h before
the induction of pancreatitis (Fig. 3A and Fig. 3B, SPRC
12 h+Cae). Quantitation of alveolar thickening (on a score of 0–
4), an evidence of lung injury, showed that Veh+Cae treated mice
had 3.560.3 alveolar thickening, compared with 0.3860.1 for
Control, 1.560.3 for SPRC 3 h+Cae, and 3.560.3 for SPRC
12 h+Cae. Thus, treatment with SPRC 10 mg/kg given 3 h
before the induction of pancreatitis resulted in a marked reduction
in the severity of pancreatitis-associated lung injury.
Effect of SPRC on pancreatic and pulmonary cytokines
Cytokines, one of the major inflammatory mediators, play a
critical role in the pathogenesis of pancreatitis and more so in the
subsequent inflammatory damage. Based on our initial data with
SPRC treatment given at different time points before the
induction of pancreatitis, we decided to see if the reduction in
pancreatic and pulmonary inflammation with SPRC administered
3 h prior to AP had any effect on cytokine levels in pancreas and
lung. As expected, pro-inflammatory cytokines (IL-1b and IL-6)
were significantly increased in pancreas as well as lung tissue in
Figure 2. Effect of SPRC treatment on pancreatic inflammation. A. myeloperoxidase (MPO) activity. B. histology. Acute pancreatitis was
induced by intraperitoneal (i.p.) administration of caerulein (50 mg/kg, hourly for 10 h). Mice were pre-treated with vehicle or SPRC (10 mg/kg, i.p.),
either 3 h or 12 h before the induction of pancreatitis. One hour after the last caerulein injection, mice were killed by a lethal dose of pentobarbitone
(50 mg/kg, i.p.) and pancreatic MPO activity and histology were evaluated as described in ‘‘Materials and methods’’. Key: CTRL, animals injected only
with saline (i.p., hourly for 10 h) without the induction of pancreatitis; Veh+Cae, pre-treatment with vehicle (distilled water) before the induction of
pancreatitis; SPRC 3 h+Cae, SPRC injected 3 h before the induction of pancreatitis; SPRC 12 h+Cae, SPRC injected 12 h before the induction of
pancreatitis. Results shown are the mean 6 s.e.m., n=10 mice per group. Arrow shows oedema and infiltration of inflammatory cells.
*P,0.05 when
compared to the CTRL group;
#P,0.05 when compared to the Veh+Cae group. CTRL, control; Cae, caerulein; Veh, vehicle; SPRC, S-propargyl-cysteine.
doi:10.1371/journal.pone.0032574.g002
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upper and middle panels). Interestingly, these pro-inflammatory
cytokines were significantly reduced in mice pretreated with SPRC
3 h before the induction of pancreatitis (Fig. 4, upper and middle
panels).
Pancreatic anti-inflammatory cytokine IL-10 was significantly
lowered in vehicle treated group compared to saline control mice
but this trend was not observed in the corresponding lungs (Fig. 4,
lower panel). However, SPRC treatment 3 h before the induction
of pancreatitis significantly increased both pancreatic and lung IL-
10 levels compared to the corresponding values in vehicle treated
group (Fig. 4, lower panel).
Effect of SPRC on plasma H2S concentration
Plasma H2S concentration was measured 1 h after the last
injection of saline/caerulein. There was a significant increase in
plasma H2S concentration in the AP mice pretreated with either
vehicle or SPRC (injected 3 h before AP) compared to saline
control group (Fig. 5). However among the mice subjected to AP,
plasma H2S concentration was significantly lower in mice
Figure 3. Effect of SPRC on pancreatitis-associated lung injury. A. myeloperoxidase (MPO) activity. B. histology. Acute pancreatitis was
induced by intraperitoneal (i.p.) administration of caerulein (50 mg/kg, hourly for 10 h). Mice were pre-treated with vehicle or SPRC (10 mg/kg, i.p.),
either 3 h or 12 h before the induction of pancreatitis. One hour after the last caerulein injection, mice were killed by a lethal dose of pentobarbitone
(50 mg/kg, i.p.) and lung MPO activity and histology were evaluated as described in ‘‘Materials and methods’’. Key: CTRL, animals injected only with
saline (i.p., hourly for 10 h) without the induction of pancreatitis; Veh+Cae, pre-treatment with vehicle (distilled water) before the induction of
pancreatitis; SPRC 3 h+Cae, SPRC injected 3 h before the induction of pancreatitis; SPRC 12 h+Cae, SPRC injected 12 h before the induction of
pancreatitis. Results shown are the mean 6 s.e.m., n=10 mice per group.
*P,0.05 when compared to the CTRL group;
#P,0.05 when compared to
the Veh+Cae group. CTRL, control; Cae, caerulein; Veh, vehicle; SPRC, S-propargyl-cysteine.
doi:10.1371/journal.pone.0032574.g003
SPRC in Acute Pancreatitis
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32574pretreated with SPRC (injected 3 h before AP) compared to
vehicle treated group (Fig. 5).
Discussion
SPRC is a newly synthesized H2S donor and is a structural
analog of SAC. We aimed to investigate the therapeutic potential
of SPRC in caerulein-induced AP. SPRC was injected at two
different time points, either 3 or 12 h before the induction of AP.
Results showed that pancreatic injury, as evidenced by plasma
amylase, pancreatic MPO and histology and pulmonary injury, as
evidenced by lung MPO and histology were significantly
ameliorated in the mice treated with SPRC 3 h prior to the
induction of pancreatitis. Administration of SPRC 12 h before AP
induction, on the other hand, was not very effective in protecting
against AP and associated lung injury, possibly because the
therapeutic window was missed. In addition we evaluated if the
improvement in pancreatic and pulmonary inflammation with
SPRC given 3 h before induction of AP had any effects on
pancreas and lung cytokine levels. Cytokines play a critical role in
the early pathophysiological events of the disease by recruiting
more inflammatory cells from the peripheral blood to the site of
injury [31–33]. A recent clinical study showed a clear relationship
between MPO, severity of AP and the blood cytokine levels [34].
Prolonged increase in MPO activity is reported to indicate
continued neutrophil activation, with the liberation of cytokines
and other biologically active substances like reactive oxygen
species [34]. We observed a significant reduction in the pro-
inflammatory cytokines (IL-1b and IL-6) in pancreas and lung of
mice treated with SPRC 3 h before the induction of AP compared
to the mice pretreated with vehicle.
Pancreatic and pulmonary anti-inflammatory cytokine Inter-
leukin-10 (IL-10) levels were significantly increased in mice
pretreated with SPRC compared to vehicle treated group. IL-10
is a potent inhibitor of cytokines and has been shown to attenuate
pancreatitis in animal models. Systemic administration of
adenoviral vectors expressing IL-10 significantly reduced the
degree of pancreatic and liver injury in mice models of acute
Figure 4. Effect of SPRC on pancreatic and pulmonary cytokines. Acute pancreatitis was induced by intraperitoneal (i.p.) administration of
caerulein (50 mg/kg, hourly for 10 h). Mice were pre-treated with vehicle or SPRC (10 mg/kg, i.p.) 3 h before the induction of pancreatitis. One hour
after the last caerulein injection, mice were killed by a lethal dose of pentobarbitone (50 mg/kg, i.p.) and pancreatic and lung cytokine levels were
analyzed as described in ‘‘Materials and methods’’. Key: CTRL, animals injected only with saline (i.p., hourly for 10 h) without the induction of
pancreatitis; Veh+Cae, pre-treatment with vehicle (distilled water) before the induction of pancreatitis; SPRC 3 h+Cae, SPRC injected 3 h before the
induction of pancreatitis. Results shown are the mean 6 s.e.m., n=8–10 mice per group.
*P,0.05 when compared to the CTRL group;
#P,0.05 when
compared to the Veh+Cae group. CTRL, control; Cae, caerulein; Veh, vehicle; SPRC, S-propargyl-cysteine.
doi:10.1371/journal.pone.0032574.g004
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for prevention of AP after post-endoscopic retrograde cholangio-
pancreatography is still controversial [36,37]. Collectively, our
results demonstrated that SPRC injected 3 h prior to the induction
of AP showed a beneficial effect on pancreatic and lung injury
along with modulating inflammatory cytokines.
Furthermore, we investigated if SPRC treatment affected
plasma H2S levels in AP and the mechanism by which
inflammation was modulated by SPRC. SPRC, like SAC, could
potentially influence the synthesis of endogenous H2S. In vitro,
SPRC was found to increase H2S synthesizing enzyme activity in
normal pancreatic acini compared to the vehicle control, but the
difference was not significant in the presence of caerulein hyper-
stimulation (unpublished data). However, while we observed a
significant increase in plasma H2S concentration in AP-induced
mice treated with vehicle, SPRC injected 3 h before AP lowered
this increase. As expected, high plasma H2S concentration
observed in vehicle treated mice after induction of AP was pro-
inflammatory and damaging. Administration of SPRC 3 h before
AP induction and thus the slow release of H2S could have
inhibited CSE by a feedback mechanism resulting in significantly
lower levels of H2S compared to the vehicle treated mice.
Administration of a slow H2S releasing compound has previously
been shown to be associated with a decrease in endogenous H2S
formation [14]. Evidently, further studies are needed to explore
the mechanisms of SPRC effects in AP in detail.
In conclusion, SPRC 10 mg/kg injected 3 h prior to induction
of AP ameliorated the disease by reducing the inflammatory cell
infiltration in pancreas and lung and by modulating pro- and anti-
inflammatory cytokine profile in plasma. Thus SPRC provides a
valuable lead for the treatment of AP. It could be postulated that
the beneficial effects of SPRC in AP could be by virtue of its slow
release of endogenous H2S and a possible negative feedback
mechanism on CSE.
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